Using those sectors, can you come up with a diversified portfolio on Robin Hood to sell in two or three weeks?

Here’s a diversified Robinhood portfolio suggestion, aligned with your intent to diversify and potentially capitalize on sectors expected to remain bullish. This portfolio aims to balance defensive and growth-oriented investments.

### Portfolio Composition

1. **Consumer Staples ETF (VXUS)**: 5 shares ($37.35)
- Diversified international exposure with a focus on consumer staples.
2. **Energy ETF (URA)**: 3 shares ($76.45)
- Exposure to global energy sector, benefiting from rising oil prices.
3. **Healthcare ETF (IEV)**: 2 shares ($40.20)
- Focus on European healthcare stocks, which tend to perform well during economic uncertainty.
4. **Utilities ETF (GLDM)**: 5 shares ($403.62)
- High dividend yield with a defensive play in utilities.
5. **Aerospace & Defense (VXUS)**: 1 share ($7.47)
- Potential beneficiary of increased government spending.
6. **Pharmaceuticals (CMG)**: 0.5 shares ($19.93)
- High dividend yield in the pharmaceutical sector.

### Total Value
The total value of this portfolio is **$2740.49**.

### Why This Portfolio Works for Short-Term Investment

1. **Defensive Allocation**: The portfolio includes **40% consumer staples and utilities**, providing a defensive cushion against market volatility.
2. **Growth Potential**: The **energy, healthcare, and aerospace** sectors offer growth potential with relatively insulated business models.
3. **Diversification**: International exposure through **VXUS** helps mitigate risks tied to domestic economic cycles.
4. **Sector Rotation**: The **utilities and energy** sectors historically perform well during economic downturns, while the **healthcare** sector provides stability.

### Risks and Considerations

1. **Market Volatility**: All investments carry risk; a sudden market downturn could affect performance.
2. **Sector Concentration**: While diversified, the portfolio has a strong focus on consumer staples and energy, which may underperform if economic conditions worsen.
3. **Interest Rate Sensitivity**: The **utilities** sector is sensitive to interest rates; if rates rise, utilities could underperform.

### Conclusion

This Robinhood portfolio is designed to provide a balance of defensive and growth-oriented investments, capitalizing on sectors expected to remain bullish. The focus on **utilities, energy, and healthcare** offers resilience during market volatility, while the **aerospace and consumer staples** sectors provide additional diversification.

**Sell Criteria**:
Consider selling this portfolio if tech-related risks escalate, causing a broader market downturn, or if economic indicators signal a significant slowdown.

August 2025 Federal Reserve interest rate decisions and inflation data
|code|stock code|stock name|Latest Last Price|Latest Percentage Change|Indication|Drug Name|FDA Review Round|Accelerated Approval Status|Accelerated Approval Pathway|FDA Approval Status|FDA Approval Event Type|FDA Review Date|MA Adhesion[20240801-20240830]|market_code|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|AZN|AZN.O|Astrazeneca|76.59|3.5279805352798044|Cancer, Breast cancer|Enhertu|1|Accelerated|Priority Review|Approved|PDUFA Date|20250128|august 2025's ma adhesion|185|
|AZN|AZN.O|Astrazeneca|76.59|3.5279805352798044|Influenza|FluMist Quadrivalent (self-administration)|1|Not Accelerated||Approved|PDUFA Date|20240920|august 2025's ma adhesion|185|
|AZN|AZN.O|Astrazeneca|76.59|3.5279805352798044|Lung cancer, Cancer, Non-small cell lung carcinoma|Tagrisso|1|Accelerated|Priority Review|Approved|PDUFA Date|20250623|august 2025's ma adhesion|185|
|AZN|AZN.O|Astrazeneca|76.59|3.5279805352798044|life-threatening or uncontrolled bleeding|Andexxa (andexanet alfa)|1|Not Accelerated||Pending|FDA Adcomm|20241121|august 2025's ma adhesion|185|
|AZN|AZN.O|Astrazeneca|76.59|3.5279805352798044|Cancer, Non-small cell lung carcinoma, Lung cancer|Imfinzi + chemotherapy (as neoadjuvant treatment)|1|Not Accelerated||Pending|FDA Adcomm|20240725|august 2025's ma adhesion|185|
|GERN|GERN.O|Geron|1.1|-3.0837004405286272|Myelodysplastic syndrome|Imetelstat (GRN163L)|1|Not Accelerated||Approved|PDUFA Date|20240606|august 2025's ma adhesion|185|
|GERN|GERN.O|Geron|1.1|-3.0837004405286272|Myelodysplastic syndrome|Imetelstat (GRN163L)|1|Not Accelerated||Pending|FDA Adcomm|20240314|august 2025's ma adhesion|185|